IP Library Granted Patent US 11,261,491
Granted Patent B2
US 11,261,491 · App. 16/504,672 · Granted Mar 1, 2022

Methods and compositions for measuring beta cell death

Inventors: Kevin Ferreri (Culver City, CA); Mohamed I. Husseiny Elsayed (Torrance, CA)
Assignee: City of Hope
C12Q1/6883C12Q2600/154
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,261,491
App. No.
16/504,672
Granted
Mar 1, 2022
Kind
B2
Abstract

Provided herein are, inter alia, nucleic acids, methods, and kits for detecting unmethylated DNA in body fluid sample of a subject. The disclosure includes compositions, methods, and kits for detecting unmethylation at a CpG site in an insulin gene promoter of a subject.

Claims (15)

1. A nucleic acid comprising SEQ ID NO: 1, 2, 3, or 4.

2. A nucleic acid complex comprising the nucleic acid of claim 1 , wherein said SEQ ID NO: 1, 2, 3, or 4 is contacted to a complementary deoxyribonucleic acid (DNA) sequence to form a hybridized nucleic acid complex, wherein said complementary DNA sequence comprises uridine.

3. The nucleic acid complex of claim 2 , wherein said nucleic acid is hybridized to a CpG site of said complementary DNA sequence.

4. A deoxyribonucleic acid (DNA) comprising a uridine that is hybridized to a first nucleic acid and a second nucleic acid each independently comprising SEQ ID NO: 1, 2, 3, or 4, to form a hybridized DNA with SEQ ID NO: 1, 2, 3, or 4, wherein said first and said second nucleic acids do not simultaneously comprise the same SEQ ID NO: 1, 2, 3, or 4.

5. The DNA of claim 4 , wherein said first nucleic acid comprises SEQ ID NO: 1 and said second nucleic acid comprises SEQ ID NO: 2.

6. The DNA of claim 4 , wherein said first nucleic acid comprises SEQ ID NO: 3 and said second nucleic acid comprises SEQ ID NO: 4.

7. The DNA of claim 4 , wherein said DNA is derived from a biological sample.

8. The DNA of claim 7 , wherein said biological sample is blood.

9. The DNA of claim 8 , wherein said blood is whole blood, plasma, or serum.

10. A kit comprising a first nucleic acid and a second nucleic acid each independently comprising SEQ ID NO: 1, 2, 3, 4, 5, or 6, wherein said first and said second nucleic acids do not simultaneously comprise the same SEQ ID NO: 1, 2, 3, 4, 5, or 6.

11. The kit according to claim 10 , wherein said first nucleic acid comprises SEQ ID NO: 1 and said second nucleic acid comprises SEQ ID NO: 2.

12. The kit according to claim 10 , wherein said first nucleic acid comprises SEQ ID NO: 3 and said second nucleic acid comprises SEQ ID NO: 4.

13. The kit according to claim 10 , wherein said first nucleic acid comprises SEQ ID NO: 5 and said second nucleic acid comprises SEQ ID NO: 6.

14. The kit according to claim 10 , further comprising: enzymes, reagents for deamination of cytosine, buffers, vials, plasmid vectors, control DNA, devices for collecting blood and/or tissue samples, or reagents for labeling DNA, or any combinations thereof.

15. The kit according to claim 14 , wherein the enzymes are selected from the group consisting of: thermostable DNA polymerase enzymes, restriction enzymes, and combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2019
From: FERRERI, KEVIN; HUSSEINY ELSAYED, MOHAMED I.
To: CITY OF HOPE
Reel/Frame 050202/0672 →
Continuity (3)
Division 15093359 · Apr 7, 2016
Provisional Application 62144816 · Apr 8, 2015
Related Publication 20200149106A1 · May 14, 2020